GLP-1 and Muscle Loss: What the Evidence Actually Shows

Most people searching this question are asking about Ozempic or Wegovy, which are brand-name products containing semaglutide, or Mounjaro and Zepbound, which contain tirzepatide. The body-composition research cited on this page was conducted on those brand-name products.

Protocol MD prescribes compounded semaglutide and tirzepatide, which is not the same thing as the brand-name products. Compounded medications are not FDA-approved, and they were not the products studied in those trials. The approvals and trial results belonging to the brand-name products do not transfer to a compounded version, and anyone telling you otherwise is overstating what is known.

What the trial data can reasonably inform is the mechanism — how these molecules affect appetite, intake and therefore body composition. That mechanism is what the rest of this page is about.

GLP-1 medications cause lean mass loss, and some of that lean mass is muscle. In the semaglutide body-composition data, lean mass accounted for a substantial minority of total weight lost. The exact proportion varies with the population, the scan method and how much total weight was lost, and published figures differ enough that a single headline percentage is not worth quoting. Tirzepatide data sits in a similar range.

But "lean mass" is a DEXA scan category, not a synonym for muscle. It includes intracellular water, stored glycogen and its bound water, the blood volume that supports a larger body, and the connective and structural tissue that supported the fat you no longer carry. When a body gets meaningfully smaller, some of that scaffolding goes with it, and its loss is not a functional problem.

This is why the honest framing is proportional rather than alarming. The concern is not that the number on the lean-mass line moves. It is whether you finish at a lower weight with less strength than you started with — and that outcome is substantially within your control.

The mechanism is not that semaglutide or tirzepatide attacks muscle tissue. It is that these medications work by reducing how much you eat, and eating substantially less does two things to muscle at once.

First, total protein intake usually falls along with everything else. Appetite suppression is indiscriminate — it does not preferentially spare the protein on the plate. Second, a sustained calorie deficit reduces the rate of muscle protein synthesis, so the balance between building and breaking down tissue shifts.

Add the fact that most people do not start resistance training the week they start a GLP-1, and the result is predictable: the body has less reason to keep muscle it is not using and less raw material to maintain it with.

Two interventions have real support behind them, and neither is a supplement.

Resistance training is the strongest signal you can send that muscle should be kept. A 2024 review in Diabetes Care examined exactly this question — whether resistance exercise can optimise body-composition changes during incretin-based weight loss — and the direction of the evidence favours training during the weight-loss phase rather than after it.*

Protein intake is the other. Eating less overall makes protein the thing most worth protecting on the plate, which in practice means building meals around it rather than fitting it in around everything else. That is harder on a medication that suppresses appetite, and it is the single most common place patients on a GLP-1 slip.

Rate of loss matters too. Faster weight loss tends to cost proportionally more lean mass, which is a reason to treat an unusually rapid drop as something to discuss rather than celebrate.

There is no strong evidence that one of these agents is meaningfully kinder to lean mass than the other at comparable amounts of total weight lost. Tirzepatide generally produces more total weight loss, so the absolute lean mass change can be larger simply because the overall change is larger — that is arithmetic, not a difference in how the drugs treat muscle.

Comparisons that claim a clear winner on this specific measure are usually comparing across trials with different populations and scan protocols, which is not a comparison that holds. We cover the broader differences between the two in our guide to semaglutide versus tirzepatide.

Scale weight cannot tell you what you lost. A scale that reads eight pounds lighter reports the same number whether that was mostly fat or substantially muscle, which is why weight alone is a poor instrument for this particular question.

What is more informative is tracking strength over time — whether the weights you handle are holding or falling — alongside periodic bloodwork. Protocol MD's physician-read bloodwork panels cover the metabolic markers that give context to a weight-loss phase, and we discuss calorie intake on a GLP-1 separately because getting that wrong is what drives most of the avoidable lean-mass loss.

Disclosure worth stating plainly: Protocol MD prescribes compounded semaglutide and tirzepatide through our programs, so we have a commercial interest in how you read this page. The evidence above is cited so you can check it rather than take our word for it.

The long-term functional consequences are genuinely unsettled. Most body-composition data comes from trials running 68 weeks or less, measured by DEXA, which reports tissue compartments rather than strength or physical function. Very few studies have measured what people can actually do at the end.

It is also unclear how much lean mass returns when weight stabilises, or after stopping. That matters, and the honest position today is that we are reasoning from mechanism and short-term scans rather than from long-horizon functional outcomes.

Muscle is the tissue you will want at the other end of this. It is worth protecting deliberately rather than hoping it survives the process.